The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2026 | CONCORDE study explores tumor evolution and biomarkers in radiotherapy
Alastair Greystoke, PhD, MBChB, MRCP, Newcastle University, Newcastle, UK, comments on the CONCORDE study (NCT04550104), which aims to learn as much as possible about each patient through multiple blood samples and scan analyses to assess tumor evolution and immune response to radiotherapy and new treatments. The trial will also utilize a novel platform analyzing these samples to predict treatment responses and identify potential biomarkers for personalized treatment approaches. This interview took place at the 2026 British Thoracic Oncology Group (BTOG) congress in Edinburgh, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
When we set up Concord, we thought it was key to learn the most about every single patient that was going on this study. And our patients have been very generous. They’ve given multiple blood samples throughout the study, and that includes analysis of circulating tumour DNAs, white blood cells to look at the immune environment, but also access to all the scans they have to assess the tumour during treatment and actually when on the treatment couch with cone beam CT...
When we set up Concord, we thought it was key to learn the most about every single patient that was going on this study. And our patients have been very generous. They’ve given multiple blood samples throughout the study, and that includes analysis of circulating tumour DNAs, white blood cells to look at the immune environment, but also access to all the scans they have to assess the tumour during treatment and actually when on the treatment couch with cone beam CT. I’m working with a really talented team of scientists to set up what we call Transconcord, which is going to be analyzing those samples, those blood samples, looking at how the tumour evolves in response to radiotherapy, how the immune system responds in response to the radiotherapy and the new drugs we’re using, and how we can monitor this and predict it using some of the radiological imaging. What we hope to provide in the long term is a multi-modality biomarker platform that can help predict which patient should receive radiotherapy alone, which should receive a drug alongside, which of the DNA damage repair inhibitors alongside, which should receive immunotherapy, and how we can best monitor their response to treatment so we can develop these new drugs most quickly for patients in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
